Penalized by a disappointing fourth quarter, the Tunisian pharmaceutical industry Company (SIPHAT) saw its annual turnover fall by 18% to 7.7 million dinars in 2024, compared with 9.5 million dinars in 2023. Sales in the fourth quarter of 2024 were 42% lower than in 2023, due to a 95% drop in sales of prescription drugs. […]

The post Tunisia: SIPHAT crumbles under debts of more than 128 million dinars appeared first on African Manager.